Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

K. Abou‐Alfa, Ghassan; H. Schwartz, Lawrence; Ricci, Sergio; Amadori, Dino; Santoro, Armando; Figer, Arié; De Grève, Jacques; Douillard, Jean‐Yves; Lathia, Chetan; Schwartz, Brian; Taylor, I; Moscovici, M.; B. Saltz, Leonard

doi:10.1200/jco.2005.01.3441

Public

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Published in Journal of Clinical Oncology • Aug 15, 2006

Authors:

Ghassan K. Abou‐Alfa

Lawrence H. Schwartz

Sergio Ricci

Abstract

PURPOSE: This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients. METHODS: Patients with inoperable HCC, no prior systemic ...

Subject

Sorafenib

Medicine

Hepatocellular carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!